Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 2, 2004, Pages 599-605

  Wu, Lin ^a   Shryock, John C ^b   Song, Yejia ^b   Li, Yuan ^a   Antzelevitch, Charles ^c   Belardinelli, Luiz ^a  

^a CV THERAPEUTICS INC   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANEMONE TOXIN 2; ANTIARRHYTHMIC AGENT; RANOLAZINE; TOXIN; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; GUINEA PIG; HEART; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HYPOTHESIS; IN VITRO STUDY; LONG QT SYNDROME; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; SODIUM CURRENT; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; GUINEA PIGS; LONG QT SYNDROME; MALE; PIPERAZINES;

EID: 3342882854     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.066100     Document Type: Article

References (32)

1. Antzelevitch C, Shimizu W, Yan G-X, Sicouri S, Weissenburger J, Nesterenko VV, Burashnikov A, Di Diego J, Saffitz J, and Thomas GP (1999) The M cell: its contribution to the ECG and to normal and abnormal electrical function in the heart. J Cardiovasc Electrophysiol 10:1124-1152.
2. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, and Romey G (1996) K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature (Lond) 384:78-80.
3. Belardinelli L, Antzelevitch C, and Vos MA (2003) Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24:619-625.
4. Bennett PB, Yazawa K, Makita N, and George AL Jr (1995) Molecular mechanism for an inherited cardiac arrhythmia. Nature (Lond) 376:683-685.
5. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, and Wolff AA (2004) Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. J Am Med Assoc 291:309-316.
6. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, and Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803.
7. Gralinski MR, Chi L, Park JL, Friedrichs GS, Tanhehco EJ, McCormack JG, and Lucchesi BR (1996) Protective effects of ranolazine on ventricular fibrillation induced by activation of the ATP-dependent potassium channel in the rabbit heart. J Cardiovasc Pharmacol Ther 1:141-148.
8. Hondeghem LM and Snyders DJ (1990) Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81:686-690.
9. Hondeghem LM, Carlsson L, and Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103:2004-2013.
10. Isenberg G and Ravens U (1984) The effects of the Anemonia sulcata toxin (ATX II) on membrane currents of isolated mammalian myocytes. J Physiol (Lond) 357:127-149.
11. Louis AA, Manousos IR, Coletta AP, Clark AL, and Cleland JG (2002) Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact of nicorandil on angina. Combination assessment of ranolazine in stable angina. Enhancing recovery in coronary heart disease patients. Assessment of cardioversion using transoesophageal echocardiography. Azimilide post-infarct survival evaluation. Randomized evaluation of mechanical assistance for treatment of chronic heart failure. Eur J Heart Fail 4:111-116.
12. Makita N, Horie M, Nakamura T, Ai T, Sasaki K, Yokoi H, Sakurai M, Sakuma I, Otani H, Sawa H, et al. (2002) Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 106:1269-1274.
13. Marban E (2002) Cardiac channelopathies. Nature (Lond) 415:213-218.
14. Pepine CJ and Wolff AA (1999) A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 84:46-50.
15. Priori SG, Napolitano C, Cantu F, Brown AM, and Schwartz PJ (1996) Differential Response to Na+ Channel blockade, β-adrenergic stimulation and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long QT syndrome. Circ Res 78:1009-1015.
16. Roden DM (2000) Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 11:938-940.
17. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96:195-215.
18. Sasyniuk BI, Valois M, and Toy W (1989) Recent advances in understanding the mechanisms of drug-induced torsades de pointes arrhythmias. Am J Cardiol 64:29J-32J.
19. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, et al. (2001) Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103:89-95.
20. Shaffer D, Singer S, Korvick J, and Honig P (2002) Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 35:197-200.
21. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, and Blanar MA (1997) Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. Circulation 96:1733-1736.
22. Shimizu W and Antzelevitch C (1997) Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 96:2038-2047.
23. Na in guinea pig ventricular myocytes. Antagonism by ranolazine. J Cardiovasc Pharmacol, in press.
24. Studenik CR, Zhou Z, and January CT (2001) Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome. Br J Pharmacol 132:85-92.
25. Sun ZQ, Thomas GP, and Antzelevitch C (2001) Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J Cardiovasc Electrophysiol 12:472-478.
26. Undrovinas AI, Maltsev VA, Kyle JW, Silverman N, and Sabbah HN (2002) Gating of the late Na+ channel in normal and failing human myocardium. J Mol Cell Cardiol 34:1477-1489.
27. van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, van der Hulst FF, Molenschot MM, Wellens HJ, and Vos MA (2001) Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104:2722-2727.
28. Vos MA, van Opstal JM, Leunissen JD, and Verduyn SC (2001) Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. Pharmacol Ther 92:109-122.
29. Wang DW, Yazawa K, Makita N, George AL Jr, and Bennett PB (1997) Pharmacological targeting of long QT mutant sodium channels. J Clin Investig 99:1714-1720.
30. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, and Keating MT (1995) SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80:805-811.
31. Zicha S, Moss I, Allen B, Varro A, Papp J, Dumaine R, Antzelevich C, and Nattel S (2003) Molecular basis of species-specific expression of repolarizing K+ currents in the heart. Am J Physiol 285: H1641-H1649.
32. Zygmunt AC, Thomas GP, Belardinelli L, Blackburn B, and Antzelevitch C (2002) Ranolazine produces ion channel effects similar to those observed with chronic amiodarone in canine ventricular myocytes (Abstract). Pacing Clin Electrophysiol 24:626.